Eli Lilly Targets Expanding Beyond Weight-Loss Boom With Multi-Billion Dollar Vaccine Push
Eli Lilly’s decision to spend nearly $4 billion acquiring three vaccine-focused biotechnology companies marks a significant strategic expansion for the pharmaceutical giant as it seeks to reduce long-term dependence on the booming obesity drug market and strengthen its position in future areas of infectious disease prevention. The acquisitions signal how major drugmakers are increasingly using…









